Mycofit Tablet (Mycophenolate Mofetil) | Used to Prevent Organ Rejection After Transplant

Precaution

• Use only under specialist supervision: Mycofit should be taken exactly as prescribed, particularly because it is generally part of a combination immunosuppressive regimen.
• Pregnancy: Mycophenolate Mofetil is associated with an increased risk of pregnancy loss and congenital malformations. People who can become pregnant should receive appropriate counseling regarding pregnancy prevention and planning.
• Infections: The medicine suppresses the immune system and can increase susceptibility to bacterial, viral, fungal, and other infections.
• Regular blood tests: Blood counts may need to be monitored because Mycophenolate Mofetil can cause abnormalities such as neutropenia and other blood-cell disorders.
• Gastrointestinal problems: Inform your doctor if you have a history of gastrointestinal disease because serious complications such as ulceration, bleeding, or perforation can occur.
• Existing infection: Tell your doctor about any current or recurrent infection before treatment.
• Viral infections: Patients may experience new viral infections or reactivation of previous infections, including certain hepatitis infections.
• Cancer risk: Long-term immunosuppression is associated with an increased risk of lymphoma and other malignancies, particularly certain skin cancers.
• Sun exposure: Appropriate protection from excessive sunlight and ultraviolet exposure is advised because of the increased skin-cancer risk associated with immunosuppression.
• Vaccinations: Live attenuated vaccines should generally be avoided during treatment unless specifically advised by the treating healthcare professional.

Usage 

• Take Mycofit Tablet exactly according to the dose and schedule prescribed by your transplant specialist.
• Take it regularly at the same times each day to maintain consistent medicine levels.
• Swallow the tablet with water.
• Do not crush or alter the tablet unless your healthcare professional specifically instructs you to do so.
• Mycophenolate Mofetil is generally used together with other immunosuppressive medicines.
• The prescribed dose depends on the type of transplant, age, clinical condition, kidney function, and other medicines being used.
• Do not change the dose yourself.
• Do not stop treatment even if you feel well unless your doctor tells you to stop.
• If you miss a dose, follow the instructions provided by your transplant team rather than taking extra medicine.

Uses

• Kidney Transplantation
  Used with other immunosuppressive medicines to help prevent rejection following kidney transplantation.
• Heart Transplantation
  May be prescribed as part of an immunosuppressive regimen after heart transplantation.
• Liver Transplantation
  Used in appropriate patients following liver transplantation to help prevent rejection.
• Prevention of Organ Rejection
  Mycophenolate Mofetil reduces the immune response that can attack a transplanted organ.
• Long-Term Transplant Management
  May form part of continuing immunosuppressive treatment after transplantation, according to the transplant specialist's plan.

Side Effects

Common Side Effects

• Diarrhea
• Nausea
• Vomiting
• Abdominal discomfort or pain
• Headache
• Dizziness
• Fatigue

Serious Side Effects

• Severe or persistent infection
• High or persistent fever
• Unusual bruising or bleeding
• Severe reduction in blood-cell counts
• Severe or persistent diarrhea
• Gastrointestinal bleeding
• Severe abdominal pain

FAQs

1. What is Mycofit Tablet used for?

Mycofit Tablet contains Mycophenolate Mofetil and is used with other immunosuppressive medicines to help prevent rejection after kidney, heart, or liver transplantation.

2. How does Mycofit Tablet work?

It reduces the multiplication and activity of certain immune cells involved in the immune response against a transplanted organ.

3. Is Mycofit an immunosuppressant?

Yes. Mycophenolate Mofetil is an antimetabolite immunosuppressant.

4. Can Mycofit be stopped suddenly?

No. Do not stop it without medical advice because interruption of immunosuppressive therapy can increase the risk of organ rejection.

5. Does Mycofit increase the risk of infection?

Yes. Because it suppresses the immune system, it can increase susceptibility to infections, including opportunistic infections.

6. Does Mycofit require blood tests?

Yes. Regular blood tests may be required to monitor blood-cell counts and other aspects of treatment.

7. Can Mycofit be taken during pregnancy?

Mycophenolate Mofetil is associated with significant risks during pregnancy, including pregnancy loss and congenital malformations. Pregnancy prevention and planning should be discussed with the treating healthcare professional.

Interactions

• Magnesium- or Aluminum-Containing Antacids
  These antacids can reduce systemic exposure to Mycophenolate Mofetil. The prescribing information recommends separating administration by at least 2 hours.
• Proton Pump Inhibitors (PPIs)
  Medicines such as lansoprazole and pantoprazole can reduce mycophenolic acid exposure in some circumstances. Your doctor may monitor treatment response when these medicines are used together.
• Cholestyramine
  Cholestyramine can interfere with enterohepatic recirculation and may reduce exposure to mycophenolic acid.
• Cyclosporine
  Cyclosporine can alter mycophenolic acid exposure because of its effects on enterohepatic recirculation.
• Rifampin
  Rifampin may reduce mycophenolic acid exposure and potentially reduce the effectiveness of Mycophenolate Mofetil.
• Certain Antibiotics
  Some antibiotics, including aminoglycosides, cephalosporins, fluoroquinolones, and penicillins, may affect enterohepatic recirculation and alter mycophenolic acid exposure.
• Telmisartan
  Telmisartan may affect the metabolism of mycophenolic acid and can reduce systemic exposure.
• Sevelamer and Other Calcium-Free Phosphate Binders
  These medicines can decrease mycophenolic acid exposure. Appropriate separation from Mycofit may be required.
• Oral Contraceptives
  Mycophenolate Mofetil may reduce the effectiveness of oral contraceptives. Additional barrier contraception is recommended in the prescribing information.